The deal brings CathWorks' FFRangio system – which derives physiological assessments of the entire coronary tree from routine angiograms without the use of pressure wires or pharmacologic agents – into a cardiovascular franchise that Medtronic has been building through a sequence of tuck-in acquisitions over the past several months. Picture Courtesy: Shutterstock
